Aspartoacylase-LacZ knockin mice: An engineered model of canavan disease

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Mersmann, Nadine ^a   Tkachev, Dmitri ^a   Jelinek, Ruth ^a   Röth, Philipp Thomas ^a   Möbius, Wiebke ^b   Ruhwedel, Torben ^b   Rühle, Sabine ^a   Weber Fahr, Wolfgang ^c   Sartorius, Alexander ^c   Klugmann, Matthias ^a,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTOACYLASE; BETA GALACTOSIDASE; INOSITOL; N ACETYLASPARTIC ACID; TAURINE; AMIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN DEGENERATION; BRAIN STEM; CANAVAN DISEASE; CELL VACUOLE; CEREBELLUM; CONTROLLED STUDY; CORPUS CALLOSUM; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HETEROZYGOTE; HIPPOCAMPUS; HISTOPATHOLOGY; HOMOZYGOTE; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; OPTIC NERVE; PROTEIN EXPRESSION; SCHWANN CELL; SEX DIFFERENCE; THALAMUS; WHITE MATTER; ANIMAL; GENETICS; LACTOSE OPERON; MUTATION; SEXUAL DEVELOPMENT; TRANSGENIC MOUSE;

BACTERIA (MICROORGANISMS); MUS; RODENTIA;

AMIDOHYDROLASES; ANIMALS; CANAVAN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; LAC OPERON; MALE; MICE; MICE, TRANSGENIC; MUTATION; SEX CHARACTERISTICS;

EID: 79956307321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020336     Document Type: Article

References (44)

1. Dugas JC, Tai YC, Speed TP, Ngai J, Barres BA, (2006) Functional genomic analysis of oligodendrocyte differentiation. J Neurosci 26: 10967-10983.
2. Klugmann M, Symes CW, Klaussner BK, Leichtlein CB, Serikawa T, et al. (2003) Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport 14: 1837-1840.
3. Madhavarao CN, Moffett JR, Moore RA, Viola RE, Namboodiri MA, et al. (2004) Immunohistochemical localization of aspartoacylase in the rat central nervous system. J Comp Neurol 472: 318-329.
4. Canavan MM, (1931) Schilder's Encephalitis Periaxialis Diffusa. Arch Neurol Psychiatr 25: 299-308.
5. Kaul R, Gao GP, Balamurugan K, Matalon R, (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5: 118-123.
6. Matalon R, Michals K, Kaul R, (1995) Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 127: 511-517.
7. Klugmann M, Leichtlein CB, (2006) Clinical trials of gene therapy for Canavan Disease. In: Kaplitt MG, During MJ, editors. Gene therapy in the central nervous system San Diego Elsevier pp. 303-316.
8. Kitada K, Akimitsu T, Shigematsu Y, Kondo A, Maihara T, et al. (2000) Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J Neurochem 74: 2512-2519.
9. Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, et al. (2000) Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2: 165-175.
10. Traka M, Wollmann RL, Cerda SR, Dugas J, Barres BA, et al. (2008) Nurss a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. J Neurosci 28: 11537-11549.
11. Testa G, Schaft J, van der Hoeven F, Glaser S, Anastassiadis K, et al. (2004) A reliable lacZ expression reporter cassette for multipurpose, knockout-first alleles. Genesis 38: 151-158.
12. Bitto E, Bingman CA, Wesenberg GE, McCoy JG, Phillips GN Jr, (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104: 456-461.
13. Surendran S, Matalon R, Tyring SK, (2006) Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: Implications on diabetic neuropathy. Biochem Biophys Res Commun 11: 11.
14. Hershfield JR, Madhavarao CN, Moffett JR, Benjamins JA, Garbern JY, et al. (2006) Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. Faseb J 20: 2139-2141.
15. Hirrlinger PG, Scheller A, Braun C, Quintela-Schneider M, Fuss B, et al. (2005) Expression of reef coral fluorescent proteins in the central nervous system of transgenic mice. Mol Cell Neurosci 30: 291-303.
16. Adachi M, Schneck L, Cara J, Volk BW, (1973) Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum Pathol 4: 331-347.
17. Kirmani BF, Jacobowitz DM, Namboodiri MA, (2003) Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination. Brain Res Dev Brain Res 140: 105-115.
18. Ory-Lavollee L, Blakely RD, Coyle JT, (1987) Neurochemical and immunocytochemical studies on the distribution of N-acetyl-aspartylglutamate and N-acetyl-aspartate in rat spinal cord and some peripheral nervous tissues. J Neurochem 48: 895-899.
19. Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, et al. (2005) Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A 102: 5221-5226.
20. Kondo A, Nagara H, Akazawa K, Tateishi J, Serikawa T, et al. (1991) CNS pathology in the neurological mutant rats zitter, tremor and zitter-tremor double mutant (spontaneously epileptic rat, SER). Exaggeration of clinical and neuropathological phenotypes in SER. Brain 114: 979-999.
21. Suzuki K, (1968) Peripheral nerve lesion in spongy degeneration of the central nervous system. Acta Neuropathol 10: 95-98.
22. Jia F, Yue M, Chandra D, Keramidas A, Goldstein PA, et al. (2008) Taurine is a potent activator of extrasynaptic GABA(A) receptors in the thalamus. J Neurosci 28: 106-115.
23. Assadi M, Janson C, Wang DJ, Goldfarb O, Suri N, et al. (2010) Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol 14: 354-359.
24. Pederzolli CD, Rockenbach FJ, Zanin FR, Henn NT, Romagna EC, et al. (2009) Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab Brain Dis 24: 283-298.
25. Baslow MH, (2002) Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 40: 295-300.
26. Uldry M, Ibberson M, Horisberger JD, Chatton JY, Riederer BM, et al. (2001) Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J 20: 4467-4477.
27. Bluml S, (1999) In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. J Magn Reson 136: 219-225.
28. Cakmakci H, Pekcevik Y, Yis U, Unalp A, Kurul S, (2010) Diagnostic value of proton MR spectroscopy and diffusion-weighted MR imaging in childhood inherited neurometabolic brain diseases and review of the literature. Eur J Radiol 74: e161-171.
29. Neale JH, Olszewski RT, Gehl LM, Wroblewska B, Bzdega T, (2005) The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 26: 477-484.
30. Kamoshita S, Reed GB Jr, Aguilar MJ, (1967) Axonal dystrophy in a case of Canavan's spongy degeneration. Neurology 17: 895-898.
31. Klugmann M, Leichtlein CB, Symes CW, Serikawa T, Young D, et al. (2005) Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol Ther 11: 745-753.
32. Nave KA, (2010) Myelination and the trophic support of long axons. Nat Rev Neurosci 11: 275-283.
33. van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH, Jenster G, (2006) Gene expression profiling of the human prostate zones. BJU Int 98: 886-897.
34. Orthmann-Murphy JL, Abrams CK, Scherer SS, (2008) Gap junctions couple astrocytes and oligodendrocytes. J Mol Neurosci 35: 101-116.
35. Tacke U, Olbrich H, Sass JO, Fekete A, Horvath J, et al. (2005) Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics 36: 252-255.
36. Olson EN, Arnold HH, Rigby PW, Wold BJ, (1996) Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 85: 1-4.
37. Surendran S, Ezell EL, Quast MJ, Wei J, Tyring SK, et al. (2004) Aspartoacylase deficiency does not affect N-acetylaspartylglutamate level or glutamate carboxypeptidase II activity in the knockout mouse brain. Brain Res 6: 268-271.
38. Arun P, Madhavarao CN, Moffett JR, Hamilton K, Grunberg NE, et al. (2010) Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. J Inherit Metab Dis 33: 195-210.
39. Cerghet M, Skoff RP, Swamydas M, Bessert D, (2009) Sexual dimorphism in the white matter of rodents. Journal of the Neurological Sciences 286: 76-80.
40. Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, et al. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25: 139-140.
41. Pfaffl MW, Horgan GW, Dempfle L, (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
42. Sherman DL, Fabrizi C, Gillespie CS, Brophy PJ, (2001) Specific disruption of a schwann cell dystrophin-related protein complex in a demyelinating neuropathy. Neuron 30: 677-687.
43. Mobius W, Cooper B, Kaufmann WA, Imig C, Ruhwedel T, et al. (2010) Electron microscopy of the mouse central nervous system. Methods Cell Biol 96: 475-512.
44. Reynolds ES, (1963) The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 17: 208-212.